Literature DB >> 32227197

A Community-transmitted Case of Severe Acute Respiratory Distress Syndrome (SARS) Due to SARS-CoV-2 in the United States.

Bradley Sanville1, Rebecca Corbett1, Wesley Pidcock1, Kaitlyn Hardin2, Christian Sebat1, Minh-Vu Nguyen2, George R Thompson2, Angela Haczku1, Michael Schivo1, Stuart Cohen2.   

Abstract

This is the first known community transmission case of the novel coronavirus disease (COVID-19) in the United States, with significant public health implications. Diagnosis of COVID-19 is currently confirmed with PCR based testing of appropriate respiratory samples. Given the absence of travel or known exposure history, this patient did not meet the criteria for testing according to CDC guidelines at the time of her presentation. Since this case, any patient with severe disease (eg, ARDS or pneumonia) requiring hospitalization without an explanatory diagnosis can be tested even if no clear source of exposure is identified. While influencing national health policies for revising screening criteria, this case also highlighted significant knowledge gaps in diagnosis and treatment and a desperate need for early, widespread, fast and cheap testing for COVID-19.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; community transmission; index case; novel coronavirus

Mesh:

Substances:

Year:  2020        PMID: 32227197      PMCID: PMC7197621          DOI: 10.1093/cid/ciaa347

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

Review 1.  Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review.

Authors:  Chih-Jen Yang; Yu-Jui Wei; Hsu-Liang Chang; Pi-Yu Chang; Chung-Chen Tsai; Yen-Hsu Chen; Po-Ren Hsueh
Journal:  J Microbiol Immunol Infect       Date:  2020-10-05       Impact factor: 4.399

2.  SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques.

Authors:  Yashavanth Shaan Lakshmanappa; Sonny R Elizaldi; Jamin W Roh; Brian A Schmidt; Timothy D Carroll; Kourtney D Weaver; Justin C Smith; Anil Verma; Jesse D Deere; Joseph Dutra; Mars Stone; Sergej Franz; Rebecca Lee Sammak; Katherine J Olstad; J Rachel Reader; Zhong-Min Ma; Nancy K Nguyen; Jennifer Watanabe; Jodie Usachenko; Ramya Immareddy; JoAnn L Yee; Daniela Weiskopf; Alessandro Sette; Dennis Hartigan-O'Connor; Stephen J McSorley; John H Morrison; Nam K Tran; Graham Simmons; Michael P Busch; Pamela A Kozlowski; Koen K A Van Rompay; Christopher J Miller; Smita S Iyer
Journal:  Nat Commun       Date:  2021-01-22       Impact factor: 14.919

Review 3.  Impact of repurposed drugs on the symptomatic COVID-19 patients.

Authors:  Iqbal Hussain; Afzal Hussain; Mohamed F Alajmi; Md Tabish Rehman; Samira Amir
Journal:  J Infect Public Health       Date:  2020-12-07       Impact factor: 3.718

Review 4.  Ongoing COVID-19 Pandemic: A Concise but Updated Comprehensive Review.

Authors:  Chao Wang; Xiong Xiao; Hongyan Feng; Zhengyuan Hong; Meng Li; Ning Tu; Xuerong Li; Ke Wang; Lihong Bu
Journal:  Curr Microbiol       Date:  2021-04-13       Impact factor: 2.188

5.  SARS-CoV-2 infection induces germinal center responses with robust stimulation of CD4 T follicular helper cells in rhesus macaques.

Authors:  Sonny R Elizaldi; Yashavanth Shaan Lakshmanappa; Jamin W Roh; Brian A Schmidt; Timothy D Carroll; Kourtney D Weaver; Justin C Smith; Jesse D Deere; Joseph Dutra; Mars Stone; Rebecca Lee Sammak; Katherine J Olstad; J Rachel Reader; Zhong-Min Ma; Nancy K Nguyen; Jennifer Watanabe; Jodie Usachaenko; Ramya Immareddy; JoAnn L Yee; Daniela Weiskopf; Alessandro Sette; Dennis Hartigan-O'Connor; Stephen J McSorley; John H Morrison; Nam K Tran; Graham Simmons; Michael P Busch; Pamela A Kozlowski; Koen K A Van Rompay; Christopher J Miller; Smita S Iyer
Journal:  bioRxiv       Date:  2020-07-08

Review 6.  Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019.

Authors:  Yong-Jian Geng; Zhi-Yao Wei; Hai-Yan Qian; Ji Huang; Robert Lodato; Richard J Castriotta
Journal:  Cardiovasc Pathol       Date:  2020-04-17       Impact factor: 2.185

Review 7.  Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19.

Authors:  Sarah C J Jorgensen; Razieh Kebriaei; Linda D Dresser
Journal:  Pharmacotherapy       Date:  2020-06-28       Impact factor: 6.251

8.  Delayed Initiation of Remdesivir in a COVID-19-Positive Patient.

Authors:  Emily Hillaker; Julie J Belfer; Anamaria Bondici; Hani Murad; Lisa E Dumkow
Journal:  Pharmacotherapy       Date:  2020-05-20       Impact factor: 6.251

9.  Planning for post-pandemic cancer care delivery: Recovery or opportunity for redesign?

Authors:  Pelin Cinar; Richard Bold; Bryn A Bosslet; Daniela A Bota; Debra Burgess; Helen K Chew; Joshua G Cohen; Emad Elquza; Kathryn A Gold; Emi Kamiya; Beth Y Karlan; Rana R McKay; Sandip P Patel; Kimberly Ternavan; Jeanna Welborn; Maki Yamamoto; Hope S Rugo
Journal:  CA Cancer J Clin       Date:  2020-09-30       Impact factor: 286.130

Review 10.  Clinical studies assessing the efficacy, effectiveness and safety of remdesivir in management of COVID-19: A scoping review.

Authors:  Juan Pimentel; Cassandra Laurie; Anne Cockcroft; Neil Andersson
Journal:  Br J Clin Pharmacol       Date:  2020-12-15       Impact factor: 3.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.